Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, Buti, Sebastiano, Cattrini, Carlo, Mennitto, Alessia, Messina, Carlo, Airoldi, Chiara, Vannini, Gianmarco, Bersanelli, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273868/
https://www.ncbi.nlm.nih.gov/pubmed/34290828
http://dx.doi.org/10.1177/17562872211029784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273868/
https://www.ncbi.nlm.nih.gov/pubmed/34290828
http://dx.doi.org/10.1177/17562872211029784

Ejemplares similares